HUTCHMED (China) Limited (HK:0013) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
HUTCHMED (China) Limited has appointed Cavendish Capital Markets Limited as a joint corporate broker in London, effective January 1, 2025. This move, alongside continuing partnerships with Panmure Liberum Limited and HSBC Bank plc, reflects HUTCHMED’s strategic efforts to strengthen its financial market presence. The biopharmaceutical company focuses on developing and commercializing therapies for cancer and immunological diseases.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
